Expression of NEDD9 in pancreatic ductal adenocarcinoma and its clinical significance

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 895-899

  Xue, Yu Zheng ^a   Sheng, Ying Yue ^a   Liu, Zong Liang ^a   Wei, Zhe Qiang ^a   Cao, Hai Yan ^a   Wu, Yan Min ^a   Lu, Yu Feng ^a   Yu, Li Hua ^a   Li, Jian Ping ^a   Li, Zhao Shen ^b  

^a NANTONG UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

NEDD9; Pancreatic ductal adenocarcinoma; Prognosis

Indexed keywords

MESSENGER RNA; MOLECULAR MARKER; ONCOPROTEIN; PROTEIN NEDD9; UNCLASSIFIED DRUG; NEDD9 PROTEIN, HUMAN; PHOSPHOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; GENETICS; LIVER TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; MORTALITY; PANCREAS; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BLOTTING, WESTERN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LIVER NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREAS; PANCREATIC NEOPLASMS; PHOSPHOPROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84877142888     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0624-8     Document Type: Article

References (17)

1. Niederhuber JE, Brennan MF, Menck HR. The National Cancer Data Base report on pancreatic cancer. Cancer. 1995;76:1671-7.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin. 1997;47:5-27.
3. Spinelli GP, Zullo A, Romiti A, Di Seri M, Tomao F, Miele E, et al. Long-term survival in metastatic pancreatic cancer. A case report and review of the literature. JOP. 2006;7(5):486-91.
4. Fisher WE, Berger DH. Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int J Gastrointest Cancer. 2003;33(1):79-88.
5. Law SF, Estojak J, Wang B, Mysliwiec T, Kruh G, Golemis EA. Human enhancer of filamentation 1, a novel p130cas-like docking protein, associates with focal adhesion kinase and induces pseudohyphal growth in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16:3327-37.
6. Minegishi M, Tachibana K, Sato T, Iwata S, Nojima Y, Morimoto C. Structure and function of Cas-L, a 105-kD Crk-associated substrate-related protein that is involved in beta 1 integrin-mediated signaling in lymphocytes. J Exp Med. 1996;184:1365-75.
7. Kumar S, Tomooka Y, Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun. 1992;185:1155-61.
8. Tikhmyanova N, Little JL, Golemis EA. CAS proteins in normal and pathological cell growth control. Cell Mol Life Sci. 2010;67:1025-48. doi: 10.1007/s00018-009-0213-1.
9. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518-24. doi: 10.1038/nature03799.
10. Natarajan M, Stewart JE, Golemis EA, Pugacheva EN, Alexandropoulos K, Cox BD, et al. HEF1 is a necessary and specific downstream effector of FAK that promotes the migration of glioblastoma cells. Oncogene. 2006;25:1721-32. doi: 10.1038/sj.onc.1209199.
11. Kim M, Gans JD, Nogueira C, Wang A, Paik JH, Feng B, et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell. 2006;125:1269-81.
12. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition (1997). Union internationale contre le cancer and the American joint committee on cancer. Cancer. 1997;80:1803-4.
13. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72:2979-85.
14. Chang JX, Gao F, Zhao GQ, Zhang GJ. Expression and clinical significance of NEDD9 in lung tissues. Med Oncol. 2012;29:2654-60. doi: 10.1007/s12032-012- 0213-0.
15. Astier A, Manié SN, Law SF, Canty T, Haghayghi N, Druker BJ, et al. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells. Leuk Lymphoma. 1997;28:65-72.
16. le Thao B, Vu HA, Yasuda K, Taniguchi S, Yagasaki F, Taguchi T, et al. Cas-L was overexpressed in imatinib-resistant gastrointestinal stromal tumor cells. Cancer Biol Ther. 2009;8:683-8.
17. Iwata S, Souta-Kuribara A, Yamakawa A, Sasaki T, Shimizu T, Hosono O, et al. HTLV-I Tax induces and associates with Crk-associated substrate lymphocyte type (Cas-L). Oncogene. 2005;24:1262-71.